PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34940128-12 2021 CONCLUSIONS: Regorafenib was demonstrated to possibly exhibit antitumor activity on the breast cancer cell line via modulation of the P2X7/HIF-1alpha/VEGF, P2X7/P38, P2X7/ERK/NF-kappaB, and P2X7/beclin 1 pathways. regorafenib 13-24 mitogen-activated protein kinase 1 Homo sapiens 171-174 30761258-6 2019 Notably, we also found that regorafenib reversed HGF-induced sorafenib resistance by inhibiting ERK and STAT3, and subsequently down-regulating Snail and EMT. regorafenib 28-39 mitogen-activated protein kinase 1 Homo sapiens 96-99 34458148-8 2021 Sorafenib, lenvatinib, and cabozantinib also showed the same effects as regorafenib, while regorafenib had most potent effects on HLA-I expression, possibly dependent on its stronger inhibitory activity against the MEK/ERK pathway. regorafenib 72-83 mitogen-activated protein kinase 1 Homo sapiens 219-222 34458148-8 2021 Sorafenib, lenvatinib, and cabozantinib also showed the same effects as regorafenib, while regorafenib had most potent effects on HLA-I expression, possibly dependent on its stronger inhibitory activity against the MEK/ERK pathway. regorafenib 91-102 mitogen-activated protein kinase 1 Homo sapiens 219-222 32562663-5 2020 We found regorafenib inhibited Sirt3 and p-ERK expression in HCC cells in a dose-dependent manner. regorafenib 9-20 mitogen-activated protein kinase 1 Homo sapiens 43-46 31163381-3 2019 Regorafenib, a multikinase inhibitor, was demonstrated to inhibit tumor progression through suppression of ERK/NF-kappaB signaling in hepatocellular carcinoma cells in vitro and in vivo. regorafenib 0-11 mitogen-activated protein kinase 1 Homo sapiens 107-110 31238539-7 2019 In these studies, we also indicated that regorafenib suppressed cell growth by prompting apoptosis of osteosarcoma cells, which is mediated through inactivation of ERK and AKT signaling pathways. regorafenib 41-52 mitogen-activated protein kinase 1 Homo sapiens 164-167 31238539-10 2019 In sum, we suggest that regorafenib has potential to suppress osteosarcoma progression via inactivation of AKT and ERK mediated signaling pathway. regorafenib 24-35 mitogen-activated protein kinase 1 Homo sapiens 115-118 30801954-8 2019 In addition, regorafenib significantly inhibited tumor growth, NF-kappaB, p38, ERK activation and expression of tumor progression-associated proteins in bladder cancer in vitro and in vivo. regorafenib 13-24 mitogen-activated protein kinase 1 Homo sapiens 79-82 34458148-7 2021 Given that regorafenib directly inhibits Raf/MEK/ERK signaling, the downregulation of the MEK/ERK pathway appears to be one of the mechanisms by which regorafenib promotes STAT1 activation. regorafenib 11-22 mitogen-activated protein kinase 1 Homo sapiens 49-52 34458148-7 2021 Given that regorafenib directly inhibits Raf/MEK/ERK signaling, the downregulation of the MEK/ERK pathway appears to be one of the mechanisms by which regorafenib promotes STAT1 activation. regorafenib 151-162 mitogen-activated protein kinase 1 Homo sapiens 49-52 34458148-7 2021 Given that regorafenib directly inhibits Raf/MEK/ERK signaling, the downregulation of the MEK/ERK pathway appears to be one of the mechanisms by which regorafenib promotes STAT1 activation. regorafenib 151-162 mitogen-activated protein kinase 1 Homo sapiens 94-97 34969747-4 2022 MEK-inhibition with cobimetinib effectively silenced paradoxical MAP kinase/ERK-signaling pathway activation after regorafenib monotherapy, and resulted in a significant and durable clinical response. regorafenib 115-126 mitogen-activated protein kinase 1 Homo sapiens 76-79 29371921-10 2017 In conclusion, our study identified MALT1 to be a downstream mediator of the Raf/Erk/Elk-1 pathway and suggested that MALT1 may be a new therapeutic target for successful treatment of CCA by regorafenib. regorafenib 191-202 mitogen-activated protein kinase 1 Homo sapiens 81-84 29291014-8 2017 The pattern of upregulated proteins was similar with both drugs and indicates an activated RAF/MEK/ERK pathway, but more proteins were downregulated with sorafenib versus regorafenib. regorafenib 171-182 mitogen-activated protein kinase 1 Homo sapiens 99-102 28000898-0 2017 Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-kappaB activation in hepatocellular carcinoma cells. regorafenib 0-11 mitogen-activated protein kinase 1 Homo sapiens 76-79 29359239-5 2018 Regorafenib overcomes the growth advantage conferred by a stroma cell MM and an endothelial cell MM, co-culture systems, and abrogates growth factor-stimulated MEK, ERK, and AKT phosphorylation at nanomolar to micromolar concentrations. regorafenib 0-11 mitogen-activated protein kinase 1 Homo sapiens 165-168 29423069-1 2018 Inhibition of RAS-RAF-ERK-signaling is a major mechanism mediated by the multi-kinase inhibitors sorafenib and regorafenib, the only effective therapeutic approaches for advanced hepatocellular carcinoma (HCC). regorafenib 111-122 mitogen-activated protein kinase 1 Homo sapiens 22-25 28000898-4 2017 Inhibitors of various kinases including AKT, c-Jun N-terminal kinase (JNK), P38 and extracellular signal-regulated kinase (ERK) were used to evaluate the mechanism of regorafenib-induced NF-kappaB inactivation. regorafenib 167-178 mitogen-activated protein kinase 1 Homo sapiens 76-79 28000898-4 2017 Inhibitors of various kinases including AKT, c-Jun N-terminal kinase (JNK), P38 and extracellular signal-regulated kinase (ERK) were used to evaluate the mechanism of regorafenib-induced NF-kappaB inactivation. regorafenib 167-178 mitogen-activated protein kinase 1 Homo sapiens 84-121 28000898-4 2017 Inhibitors of various kinases including AKT, c-Jun N-terminal kinase (JNK), P38 and extracellular signal-regulated kinase (ERK) were used to evaluate the mechanism of regorafenib-induced NF-kappaB inactivation. regorafenib 167-178 mitogen-activated protein kinase 1 Homo sapiens 123-126 28000898-6 2017 We also demonstrated that regorafenib inhibited NF-kappaB activation through ERK dephosphorylation. regorafenib 26-37 mitogen-activated protein kinase 1 Homo sapiens 77-80 28000898-7 2017 Taken all together, our findings indicate that regorafenib triggers extrinsic and intrinsic apoptosis through suppression of ERK/NF-kappaB activation in SK-HEP-1 cells. regorafenib 47-58 mitogen-activated protein kinase 1 Homo sapiens 125-128 26921392-4 2016 Regorafenib, like many multikinase inhibitors, was designed to block the activities of several key kinase pathways involved in oncogenesis (Ras/Raf/MEK/ERK) and tumor angiogenesis (VEGF-receptors), and we have recently shown that it also possesses soluble epoxide hydrolase (sEH) inhibitory activity, which may be contributing to its salutary effects in patients. regorafenib 0-11 mitogen-activated protein kinase 1 Homo sapiens 152-155